However, antibodies directed to tau oligomers do show protection in α-synuclein models and it therefore remains possible that tau immunotherapy may be protective in synucleinopathies with co-existing pathologic aggregates of tau (Gerson et al., 2018). Here, SNCA is linked to synucleinopathy.